Media-OutReach Newswire Wegovy® (semaglutide 2.4mg) by Novo Nordisk is now Available in Singapore for Weight Management
Media-OutReach Newswire Rethinking Obesity: Novo Nordisk’s Latest Initiative Urges Singaporeans to Treat, Not Blame
Media-OutReach Newswire 2023 VinFuture Special Prize Laureate Prof. Daniel Drucker: Ample room remains for innovation in GLP-1 therapies
Media-OutReach Newswire Diabetes Association Unveils T-CaReMe Taipei Declaration at the Asia Diabetes International Conference
Media-OutReach Newswire The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist